v3.26.1
Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (Details) - USD ($)
1 Months Ended 3 Months Ended
Nov. 22, 2021
Dec. 31, 2023
Mar. 31, 2025
Jun. 30, 2026
Sep. 30, 2025
Jun. 30, 2025
Dec. 11, 2023
Jun. 30, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Contract assets       $ 10,231,000 $ 0      
Contract liabilities included in deferred revenue, current       94,596,000 $ 2,399,000 $ 22,979,000    
GSK | GSK-HSD License Agreement                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Initial transaction price $ 120,000,000.0              
Milestone payment receivable               $ 30,000,000.0
Milestone payment receivable upon achievement of phase two and first patient dosed in phase three 100,000,000.0              
Contract assets       0        
Contract liabilities included in deferred revenue, current       $ 0        
GSK | GSK-HSD License Agreement | Maximum                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Commercial milestone payments at first commercial sale 190,000,000.0              
Sales-related milestone payments $ 590,000,000.0              
Percentage of eligible to receive tiered royalties on net sales 20.00%              
GSK | GSK-HBV Agreement                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Initial transaction price   $ 2,700,000            
Development milestone payments     $ 2,500,000          
GSK | GSK-HBV Agreement | Maximum                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Development and sales milestone payments             $ 830,000,000.0